Novocure Ltd
Closed
SectorHealthcare
14.25 -19.99
Overview
Share price change
24h
Min
14.08
Max
14.44
Income | -47M -71M |
|---|---|
Sales | -295K 174M |
EPS | -0.62 |
Profit margin | -40.871 |
Employees | 1,605 |
EBITDA | -29M -63M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +43.42% upside |
Next Earnings | 23 lip 2026 |
|---|
Market Cap | 593M 2B |
|---|---|
Previous open | 34.24 |
Previous close | 14.25 |
News Sentiment
By Acuity
59%
41%
261 / 342 Ranking in Healthcare
Novocure Ltd Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
About Novocure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.